Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

– PDUFA action date set for October 25, 2025 –

– sNDA being reviewed under FDA’s RTOR program –

– Revumenib has the potential to become the first and only menin inhibitor approved in both R/R mNPM1 AML and R/R KMT2Ar acute leukemia –

Read more at globenewswire.com